Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Thomssen

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Breast Cancer Research and Treatment|July 29, 1999
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapseN Harbeck, C Thomssen, U Berger, et al.
Advances in Clinical Chemistry|April 24, 2008
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trialK Annecke, M Schmitt, U Euler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapyN Harbeck, U Alt, U Berger, et al.
Oncogene|June 5, 2007
Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinomaM Köbel, D Weidensdorfer, C Reinke, et al.
Thrombosis and Haemostasis|July 1, 1997
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapyM Schmitt, N Harbeck, C Thomssen, et al.
British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.
Anticancer Research|August 15, 1998
Prognostic impact of tumor biological factors on survival in node-negative breast cancerN Harbeck, P Dettmar, C Thomssen, et al.
Blut|January 1, 1989
Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2aA Tichelli, A Gratwohl, C Berger, et al.
Schweizerische Medizinische Wochenschrift|March 23, 1991
[Emergency therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF)]A Gratwohl, H Dazzi, A Tichelli, et al.
Infection|April 29, 1999
Human parvovirus B19-associated disease in bone marrow transplantationM Schleuning, G Jäger, E Holler, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Breast Cancer Research and Treatment|July 29, 1999
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapseN Harbeck, C Thomssen, U Berger, et al.
Advances in Clinical Chemistry|April 24, 2008
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trialK Annecke, M Schmitt, U Euler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapyN Harbeck, U Alt, U Berger, et al.
Oncogene|June 5, 2007
Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinomaM Köbel, D Weidensdorfer, C Reinke, et al.
Thrombosis and Haemostasis|July 1, 1997
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapyM Schmitt, N Harbeck, C Thomssen, et al.
British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.
Anticancer Research|August 15, 1998
Prognostic impact of tumor biological factors on survival in node-negative breast cancerN Harbeck, P Dettmar, C Thomssen, et al.
Blut|January 1, 1989
Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2aA Tichelli, A Gratwohl, C Berger, et al.
Schweizerische Medizinische Wochenschrift|March 23, 1991
[Emergency therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF)]A Gratwohl, H Dazzi, A Tichelli, et al.
Infection|April 29, 1999
Human parvovirus B19-associated disease in bone marrow transplantationM Schleuning, G Jäger, E Holler, et al.
Pageof 8